Tag Archive for: Domain Therapeutics

Domain Therapeutics Rebrands as Kainova Therapeutics Advancing Its Clinical Pipeline of GPCR-Modulating Therapies

/in

Kainova Therapeutics rebrand reflects expanding capabilities powering next stage of corporate growth Kainova champions scientific agility, bold ambition, and unity of purpose Montreal, Canada, Strasbourg, France, Boston, USA, January 12, 2026: Kainova Therapeutics (“Kainova” or “the Company”), a catalyst for breakthrough treatments for patients in immuno-oncology and inflammation, today announced a transformative rebrand. The new […]

Read more

Domain Therapeutics Appoints Boston-Based Pharma Leader Jean-Marie Cuillerot, M.D., as Chief Medical Officer

/in

Internationally recognized clinical strategist with proven track record in translating innovation into clinical impact joins Domain to advance its GPCR-targeting pipeline Appointment comes at a pivotal moment, following the initiation of Phase I/II development of DT-7012, a Treg-depleting anti-CCR8 antibody candidate Strasbourg, France – Montreal, Canada – Boston, United States, November 13, 2025: Domain Therapeutics […]

Read more

Domain Therapeutics Doses First Patients in Phase I / II Trial of DT-7012 Targeting CCR8 in Solid Tumors

/in

DT-7012 is a proprietary, differentiated Treg-depleting anti-CCR8 monoclonal antibody Differentiated binding capacities and competitive properties position it as a promising therapeutic to boost anti-tumor immunity, overcoming immunosuppression Strasbourg, France – Montreal, Canada – Boston, United States, October 28, 2025: Domain Therapeutics ( “Domain” or “the Company” ), the GPCR experts harnessing deep receptor biology to develop […]

Read more

Domain Therapeutics Presents Novel Data Addressing Key Challenges in Oncology at AACR 2025

/in

Phase I clinical results of DT-9081, an EP4 receptor antagonist, allowed selection of recommended Phase II dose (RP2D) for further development in solid tumors Preclinical data of DT-7012 position this Treg depleting anti-CCR8 antibody as a highly differentiated candidate for clinical development Preclinical findings demonstrate high potential of the PAR2 biased negative allosteric modulator (NAM) […]

Read more

Domain Therapeutics to present and participate at major global healthcare conferences, March to June 2025

/in

Domain’s leadership will highlight advancements in its key programs in immuno-oncology and inflammation Key presentations on its first-in-class biased antagonist of PAR2 and best-in-class Treg-depleting anti-CCR8 antibody candidates Strasbourg, France – Montreal, Canada – Boston, United States, February 27, 2025: Domain Therapeutics (“Domain” or “the Company”), the GPCR experts harnessing deep receptor biology to develop breakthrough treatments for […]

Read more